Mirum Pharmaceuticals (NASDAQ: MIRM) Surges on Positive Volixibat Clinical Trial Results and Analyst Price Target Hike

Font: Financial Modeling Prep  • May 05, 2026

• Analyst firm Morgan Stanley raised its price target for Mirum Pharmaceuticals to $140, indicating a potential upside of 32.34% from its previous trading price.
• Mirum Pharmaceuticals announced that its experimental drug, volixibat, successfully met the primary endpoint in a Phase 2b study, significantly reducing severe itching (pruritus) in patients with primary sclerosing cholangitis (PSC).
• Following this positive news, Mirum Pharmaceuticals shares climbed 9.59% to $105.79, reaching a new 52-week high of $110.49 and boosting its market capitalization to approximately $5.31 billion.

Mirum Pharmaceuticals (NASDAQ: MIRM) is a biotechnology company dedicated to the development of innovative treatments for rare liver diseases. Its crucial work focuses on addressing conditions that currently have limited or no approved therapies. A key drug in its pipeline, highlighting its commitment to drug development, is volixibat, an experimental oral treatment designed to help patients with these specific liver conditions.

An analyst at Morgan Stanley recently increased the price target for Mirum Pharmaceuticals stock to $140 from a previous target of $130. When this analyst rating was announced, the stock's price was $105.79. This new target suggests a potential upside, or increase in value, of approximately 32.34% from that price, signaling a positive outlook for the pharmaceutical company.

This positive outlook follows significant clinical news. As highlighted by Reuters, Mirum Pharmaceuticals announced that its experimental drug, volixibat, met the main goal of a mid-stage study. The drug successfully reduced severe itching, a condition known as pruritus, in patients suffering from a type of rare liver disease, marking a significant advancement in pruritus treatment.

The VISTAS Phase 2b study specifically evaluated volixibat in patients with primary sclerosing cholangitis (PSC). According to Business Wire, the study met its primary endpoint. Dr. Joanne Quan, Mirum Pharmaceuticals' Chief Medical Officer, noted the drug showed "statistically significant and clinically meaningful reductions" in itching for this historically difficult-to-treat disease, reinforcing the strength of its clinical data.

The market reacted strongly to this news. Shares of Mirum Pharmaceuticals increased by 9.59% to $105.79, hitting a new 52-week high of $110.49 during the day. The company now has a market capitalization of approximately $5.31 billion. Market capitalization is the total value of all a company's shares, reflecting its overall stock performance and investment opportunity.